Thrombolysis in Myocardial Infarction (TIMI) Study Group

Similar documents
The Pharmacogenetics of Clopidogrel

Implications of Universal MI Definition for Clinical Trials

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.

Risk of GI Bleeding and Use of PPIs

Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!

DECLARATION OF CONFLICT OF INTEREST

תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין

FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?

P2Y 12 blockade. To load or not to load before the cath lab?

Antithrombotic therapy in the ACS patient with atrial fibrillation

Journal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36.

Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management

Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Updated and Guideline Based Treatment of Patients with STEMI

Impact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy

Why and How Should We Switch Clopidogrel to Prasugrel?

Randomized Trials. Why do Randomized Trials? Presenter Disclosure Information Christopher Cannon

Interaction Between Cigarette Smoking and Clinical Benefit of Clopidogrel

The Myth of Class Effect Antithrombotics Christopher Cannon, MD

Speaker s name: Thomas Cuisset, MD, PhD

Session Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )

New insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen

ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium

MS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI?

Clopidogrel Use in ACS and PCI: Clinical Trial Update

Double-Dose Clopidogrel in ACS: The CURRENT/OASIS-7 Trial

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy

PAR-1 Antagonist: What Do Clinical Trials Teach Us?

Flaws, Bias, Misinterpretation and Fraud in Randomized Clinical Trials

Prasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

Is Cangrelor hype or hope in STEMI primary PCI?

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor

Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary

Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events

ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ. Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον?

Clopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany

DOUBLE or TRIPLE ANTI-TROMBOTIC THERAPY in ACS. Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

Fasting or non fasting?

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

Relationships Relevant to this Presentation

Antiplatelet Therapy: how, why, when? For Coronary Stenting

'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'

The ACCELERATE Trial

ACC Rockies New Role For An Old Friend: Contemporary Insights From The ECG

INDIVIDUALIZED MEDICINE

Columbia University Medical Center Cardiovascular Research Foundation

Robert Storey. Sheffield, United Kingdom

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany

State of the Art in the ACS Atrial Fibrillation Overlap Syndrome

Stent Thrombosis Importance of Pharmacotherapy

Adults With Diagnosed Diabetes

Does COMPASS Change Practice?

Optimal Duration and Dose of Antiplatelet Therapy after PCI

STEMI Oct. 31, 2011 Core Curriculum Adjunctive/Conjunctive pharmacological therapy

Reduction in Stent Thrombosis better tablets or better stents?

Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER

ACCP Cardiology PRN Journal Club

Optimal medical therapy in patients with stable CAD

Measurement of Antiplatelet Therapeutic Efficacy

7 th Munich Vascular Conference

A Clinical Context Report

Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

A patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment

Triple Therapy After PCI in AF: A Quagmire Soon to be Drained

and Ticagrelor Professor of Medicine (Cardiology), Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients

STEMI Presentation and Case Discussion. Case #1

Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network

Journal of the American College of Cardiology Vol. 50, No. 19, by the American College of Cardiology Foundation ISSN /07/$32.

High-Sensitivity Cardiac Troponin in Suspected ACS

2. If prasugrel is found to be both more costly and more effective than clopidogrel, to assess its costeffectiveness

Novel Anticoagulation Therapy in Acute Coronary Syndrome

ISCHEMIC HEART DISEASE

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD

C-Reactive Protein Levels and Outcomes after Statin Therapy

Ticagrelor. Platelet Inhibition and Beyond. Christian W. Hamm

Prasugrel a step ahead in antiplatelet therapy

Understanding the Options Available When Prescribing Dual Antiplatelet Therapy: Dose, Duration, Reversibility, Bleeding Profiles

When and how to combine antiplatelet agents and anticoagulant?

TIMI TRIALS. Chairman: Marc S. Sabatine, MD, MPH. Director of Operations: Polly M. Fish. TIMI Study Group 11TH EDITION,

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Changing Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events

July ACCP Cardiology PRN Journal Club 7/23/2018

When analyzing the results of a large randomized, Coronary Heart Disease

Timing of angiography for high- risk ACS

Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology?

The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease

Robert Storey. Sheffield, United Kingdom

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center

Transcription:

Thrombolysis in Myocardial Infarction (TIMI) Study Group Institute of Medicine Workshop: Transforming Clinical Research in the United States October 7, 2009 Marc S. Sabatine, MD, MPH Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard Medical School

Disclosure Statement Astra Zeneca (research grant, scientific advisory boards) Bristol-Myers-Squibb (honoraria, scientific advisory boards) Eli Lilly & Daiichi-Sankyo (honoraria) Eisai (research grant) sanofi-aventis (research grant, honoraria, scientific advisory boards) Schering-Plough (research grant support) The TIMI Study Group received research grant support from: Accumetrics, Amgen, AstraZeneca, Bayer Healthcare, Beckman Coulter, Biosite, Bristol-Myers Squibb, CV Therapeutics, Eli Lilly and Company, GlaxoSmithKline, Inotek Pharmaceuticals, Integrated Therapeutics, Merck & Co., Millennium Pharmaceuticals, Novartis Pharmaceuticals, Nuvelo, Ortho-Clinical Diagnostics, Pfizer, Roche Diagnostics, sanofiaventis, Schering-Plough Research Institute.

Description The Thrombolysis in Myocardial Infarction (TIMI) Study Group is an Academic Research Organization (ARO) devoted to conducting clinical trials to improve outcomes in patients with cardiovascular disease. The group is headquartered at Brigham and Women s Hospital & Harvard Medical School Boston, MA 3

Trials to Date Phase I to Phase IV studies Initial trials NHLBI-funded, now trials industry-funded NIH grant support for ancillary studies 30 to 25,000 subjects Trial Status 45 completed trials 6 ongoing trials 7 trials in various stages of planning 4

Current Staff Physician Staff Eugene Braunwald, MD Study Chairman 12 Staff Cardiologists 3 Senior Cardiology Fellows (2-year research fellowships) Rotating BWH Research Residents Operational Staff Carolyn McCabe, BS Director 8 Project Directors & Managers Research Assistants, etc. Biostatistical Core Charles Contant, PhD Director Programmers 5

Services Academic Leadership Project Management Biostatistics Site Management Medical Hotline Regulatory Services Safety Reporting Clinical Events Committee 6

Academic Leadership (1) Review the Compound Pharmacokinetics & Pharmacodynamics Animal & Phase I Data Refine Scientific Question Unmet clinical need Potential utility of compound Current and evolving concomitant treatments Initiation of study Investigator-initiated Industry-initiated 7

Clopidogrel in STEMI Occluded Artery or Death/MI (%) 25 20 15 10 5 0 Angiographic 36% Odds Reduction P<0.0001 15.0 Clopidogrel 21.7 n=1752 n=1739 Placebo CV Death, MI, Urgent Revasc (%) 0 5 10 15 Placebo Sabatine MS et al. NEJM 2005;352:1179 Clinical 0 5 10 15 20 25 30 days Clopidogrel Odds Ratio 0.80 (95% CI 0.65-0.97) 0.97) P=0.026 20%

Clopidogrel Response Variability and Increased Risk of Ischemic Events Primary PCI for STEMI (N = 60) 5 µm ADP-induced Platelet Aggregation Death/ACS/CVA by 6 mo Baseline (%) 120 100 80 60 40 20 0 1 2 3 4 5 6 Days Clop resist 40 40 Q1 Q2 Q3 Q4 Quartiles of response Percent 30 20 10 0 6.7 P = 0.007 0 0 Q1 Q2 Q3 Q4 Matetzky S et al. Circulation. 2004;109:3171-3175. Wiviott SD, Antman EM. Circulation. 2004;109:3064-3067.

Prasugrel: more potent and predictable platelet inhibition 100.0 Inhibition of Platelet Aggregation (%) 80.0 60.0 40.0 20.0 0.0-20.0 Interpatient Variability Response to Clopidogrel Clopidogrel Responder Clopidogrel Non-responder *Responder = 25% IPA at 4 and 24 h Interpatient Variability Response to Prasugrel Brandt JT et al. Am Heart J. 2007;153:66.e9-e16.

Wiviott SD Circulation 2005 Prasugrel: Phase II Efficacy RR=0.72 [0.4,1.2] P = 0.23 P= NS MI at 30 days 10.0% 8.0% 6.0% 4.0% 7.9% 5.7% 7.0% 6.5% 4.0% 2.0% R/N 0.0% Clop Pras 40/7.5 60/10 60/15 Treatment Group Prasugrel LD/MD 20/254 37/650 14/199 13/200 10/251 11

13,608 Patients with ACS and Planned PCI Randomized to Prasugrel (60/10) vs. Clopidogrel (300/75) Endpoint (%) 15 10 5 7/2009 0 CV Death / MI / Stroke TIMI Major Non-CABG Bleeds Clopidogrel Prasugrel 0 30 60 90 180 270 360 450 Days Prasugrel Clopidogrel 12.1 9.9 2.4 1.8 HR 0.81 (0.73-0.90) P=0.0004 HR 1.32 (1.03-1.68) P=0.03 Wiviott SD et al. NEJM 2007;357:2001-15

PROVE IT TIMI 22 Death or Major CV Events (%) 30 25 20 15 10 5 0 Pravastatin 40 mg (avg achieved LDL = 95 mg/dl) Atorvastatin 80 mg (avg achieved LDL = 62 mg/dl) Circulation 2004;110:227-239 16% RR (P = 0.005) 0 3 6 9 12 15 18 21 24 27 30 Months of Follow-up Cannon et al. NEJM 2003; 350: 1495

Academic Leadership (2) Develop Study Design Study population Timing of intervention Control arm Background therapy Endpoint(s) and timing of ascertainment Statistical analysis plan Develop Key Trial Documents Protocol Case Report Form Clinical Events Committee (CEC) Charter Data Safety and Monitoring Board (DSMB) Charter 14

Academic Leadership (3) Study Startup Country & site selection Applicability to U.S. Acceptability to other countries Cost Steering Committee of National Lead Investigators Investigator Training 15

U.S. Enrollment Population STEMI w/ lytic STEMI w/ lytic NSTE-ACS Post ACS STEMI w/ lytic STEMI w/ lytic NSTE-ACS ACS NSTE-ACS Post ACS N 3002 15,078 2220 4162 20,506 3491 6560 13,608 3241 3491 Intervent. Enrollment from U.S. (%) 90 80 70 60 50 40 30 20 10 0 Hirudin vs. Heparin 59 npa vs. TPA 13 INV vs. CONS 83 Atorva vs. Prava 71 ENOX vs. UFH 1 Clopi vs. pbo 9B 17 18 22 25 28 36 38 42 46 4 Ranolaz. vs. pbo 11 Prasugrel vs. clopi 30 Phase II: OTAM vs. UFH 5 Phase II: Rivarox. vs. pbo 12 TIMI Study Group Trial

K-M estimate of time to first primary efficacy event (composite of CV death, MI or stroke) Cumulative incidence (%) 13 12 11 10 9 8 7 6 5 4 3 2 1 0 Clopidogrel Ticagrelor HR 0.84 (95% CI 0.77 0.92), p=0.0003 11.7 9.8 0 60 120 180 240 300 360 No. at risk Days after randomisation Ticagrelor 9,333 8,628 8,460 8,219 6,743 5,161 4,147 Clopidogrel 9,291 8,521 8,362 8,124 6,743 5,096 4,047 K-M = Kaplan-Meier; HR = hazard ratio; CI = confidence interval Wallentin L et al. NEJM 2009;361:1045-57.

Academic Leadership (4) Monitor Study Progress Enrollment Changes in medical landscape Aggregate event rates (efficacy & safety) Retention Lead Study Analysis Data analysis Separate copy of the database Rapidly move to presentation of data at scientific meeting Drafting of primary manuscript and subsequent analyses 18

PPI Use & Thienopyridines PPI use at randomization (n= 4529) Clopidogrel CV death, MI or stroke Prasugrel CLOPIDOGREL PPI vs no PPI: Adj HR 0.94, 95% CI 0.80-1.11 PRASUGREL PPI vs no PPI: Adj HR 1.00, 95% CI 0.84-1.20 Days O Donoghue M et al. Lancet 2009.

Clinical Events Committee Physician Staff Stephen D. Wiviott, MD Director Board-certified cardiologists, neurologists, oncologists, endocrinologists, hepatologists Seamless integration with ecrf Adjudicate Key Endpoints Efficacy & Safety, including non-cardiovascular events 2 Independent reviewers with 3 rd as needed Consistent application of definitions High-level of granularity 20

Universal MI Classification Efficacy Analysis by Universal MI Classification Cumulative Incidence (%) 8 7 6 5 4 3.4 3 2 1 0 CLOPIDOGREL PRASUGREL 29% 2.5 18% 0.4 0.3 0.1 24% 6.4 Type 1 Type 2 Type 3 Type 4 Type 5 Spont. Secondary SCD PCI-related Peri-CABG p 0.0015 0.53 -- <0.0001 -- 4.8 4a 4a 1.7 0.8 0 4b 4b 0 0.1

Core Labs Biomarker Laboratory David A. Morrow, MD, MPH - Director 2000 sq ft CLIA-accredited lab with state-of-the-art equipment Samples Baseline Follow-up Analytes Existing protein biomarkers Discovery using proteomics & metabolomics Analysis Independent risk prediction Guiding therapy 22

TIMI IIIB 8 Troponin levels in NSTE-ACS 7.5 Mortality at 42 days (%) 7 6 5 4 3 2 1 0 N=1404 1 1.7 P<0.001 χ 2 for trend 3.4 3.7 831 174 148 134 50 67 0 to <0.4 0.4 to <1.0 1.0 to <2.0 2.0 to <5.0 5.0 to <9.0 >9.0 Cardiac Troponin I 6 Antman et al. NEJM 1996; 335: 1342

D/MI/ACS at 6 mos (%) 30 25 20 15 10 5 0 Troponin T: Treatment Interaction CONS 14.5 p=ns 16.9 INV Interaction P<0.001 OR=0.52 p<0.001 24.2 14.3 N= 414 396 463 495 TnT - TnT + TnT cut point = 0.01 ng/ml (54% of Pts TnT +) Cannon NEJM 2001; 344: 1879

Lp-PLA 2 Levels and Risk of Major Adverse CV Events Adj HR = 1.33 (1.01-1.74) 1.74) P trend = 0.002 Event Rate (%) 30 25 20 15 10 17.6 21.8 22.6 22.6 26.4 5 0 654 649 657 654 651 Q1 Q2 Q3 Q4 Q5 MV Model: age, index dx,, prior MI, DM, renal, Rx arm, 30d LDL, 30d CRP O Donoghue M et al., Circulation 2006;113:1745

Hypothesis Targeting Lp-PLA 2 a Key Player in Atherosclerosis native LDL carrier of Lp-PLA 2 Lp-PLA 2 Leukocyte Lumen Atheroma Intima Oxidized LDL substrate for Lp-PLA 2 Lp-PLA 2 Darapladib (Lp-PLA 2 inhibitor) Sustained Inflammation Necrotic Core Expansion Macphee, Biochem J 1999; Zalewski and Macphee. ATVB. 2005; Shi Atherosclerosis 2007; Kolodgie, ATVB 2006 26

Core Labs Pharmacogenetics Laboratory Marc S. Sabatine, MD, MPH - Director Multiple core genotyping laboratories at Harvard & MIT Genotyping Candidate genes Arrays Analysis Risk prediction Response to therapy 27

CYP2C19 & Clinical Outcomes 1477 Patients w/ ACS and planned PCI Rx d w/ clopidogrel CV Death, MI, or Stroke (%) 14 13 12 11 10 9 8 7 6 5 4 3 2 1 CYP2C19 Reduced-Function Carriers Allele Carriers Non-carriers Non-carriers Hazard HR 1.53 Ratio 1.53 (95% (95% CI CI 1.07-2.19) P=0.014 12.1 8.0 Definite or Probable Stent Thrombosis (%) 4 3 2 1 Hazard Ratio 3.09 HR 3.09 (95% CI 1.19-8.00) P=0.015 (95% CI 1.19-8.00) Carriers CYP2C19 Reduced-Function Allele Carriers Non-carriers Non-carriers 2.6 0.8 0 0 30 90 180 270 360 450 Days After Randomization Number at Risk: Non-Carrier 1064 1009 999 980 870 755 542 Carrier 395 364 360 348 306 270 181 0 0 30 90 180 270 360 450 Days After Randomization Number at Risk: Non-Carrier 1014 1004 1001 989 885 765 547 Carrier 375 368 366 359 316 279 186 * Carriers ~30% of the population Mega JL et al. & Sabatine MS. N Engl J Med 2009;360:354-62.

Plavix Prescribing Information, Revised May 2009

Value Added by ARO Internal validity of a clinical trial Compliance with the protocol Data collection & adjudication Statistical analyses External validity or generalizability of a clinical trial Hypothesis to be tested Study population (including location) Endpoints Answering additional questions Well-characterized dataset Embedded mechanistic studies 30